AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06328972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time. Direct feeding training: with powdered milk, once a day, 5 days a week.
Study NCT06328972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-Esophageal Tube Feeding
Description: Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
Study NCT06328972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persistent Nasogastric Tube Feeding
Description: The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
Study NCT06442605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-channel uterine fibroid morcellation system
Description: Conventional laparoscopic myomectomy is performed with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids during the procedure.
Study NCT06442605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-channel specimen retrieval bag + conventional laparoscopic uterine fibroid morcellator
Description: In conventional laparoscopic myomectomy, a multi-channel specimen retrieval bag is used during the procedure, along with a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.
Study NCT05458986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch an educational video
Study NCT05458986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05458986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05458986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04489134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treament C
Description: Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Study NCT04489134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
Study NCT04489134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacocinetik
Description: Nine sampling points of 7 ml each will be taken on the first day at the CIC UIC and the last sampling point will be carried out at 24 hours from the administration the following morning.
Study NCT04489134 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic
Description: A genetic analysis to determine your characteristics for enzymes in your metabolism as well as transport proteins will be carried out. An additional 7 ml blood tube will be drawn for this purpose during the first period.
Study NCT05525260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Limonene capsule
Description: Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
Study NCT05525260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Limonene capsules(Placebo)
Description: Limonene capsules(Placebo)
Study NCT05897671 — intervention group
Intervention type: OTHER
Intervention: retrospective data analysis
Description: Macular hole closure rate, visual acuity and OCT
Study NCT05003544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: PENG BLOCK
Study NCT05003544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Intra-articular
Study NCT05003544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group C
Description: Quadratus lumborum block
Study NCT03905083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Rehab
Description: Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
Study NCT05781672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiac ultrasound with speckle tracking analysis
Description: Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography.
Study NCT05781672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cardiac ultrasound with speckle tracking analysis
Description: Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography.
Study NCT04879017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHD-286
Description: FHD-286 as a single agent
Study NCT04489134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selection visit:
Description: During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal.
Study NCT06683599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation
Description: 1 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1.
Study NCT06709404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Receive telehealth navigation intervention
Study NCT06709404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey administration
Description: Ancillary studies
Study NCT06709404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey administration
Description: Ancillary studies
Study NCT06709404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic health record review
Description: Ancillary studies
Study NCT06709404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic health record review
Description: Ancillary studies
Study NCT06709404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard caregiving experience
Study NCT04939363 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Obinutuzumab with Ibrutinib and Venetoclax
Description: 1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:
Study NCT06729489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: Endoscopy in children with refractory iron deficiency anemia
Study NCT06727968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compression Stocking
Description: Wear the compression stockin at least 6-8 hours/day
Study NCT06727968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Home-based exercise programm based on calf strengthening, mobility and stretching of lower limbs performed in standing, sitting, and laying position. Each exercise was performed 15-20 repetitions, 1 set, 3-4 days at week. In addition to these exercises, patients were instructed to walk, at least, 20 minutes at day.
Study NCT06727968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-massage
Description: Self-massage techniques alterne manual lymphatic drainage maneuvers with superficial techniques that follow the path of saphenous veins, their respective cayaids and the anastomotic system.
Study NCT06727968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prevention measures
Description: General preventive recommendations, and they were explained to the patient by the primary care physician. Those recommendations were based on the reduction in risk factors described in the Guide of Recommendations for the management of Chronic Venous Disease in Primary Care published by Semergen and semFYC.
Study NCT06729684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital health (application and smartwatch)
Description: The application allows users to conduct self-assessments for managing symptoms and side effects related to treatment. Based on the assessment results, it provides personalized self-management strategies. Additionally, users can access features for exercise, diet, and weight management.
Study NCT06728514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block group.
Description: In ESPB technique the linear transducer will be placed over the spinous process of the vertebra and a point 3 cm lateral to it are marked at the T10-T11 level before performing the block. Under aseptic precautions, the 23G spinal needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra. The transverse process of the thoracic vertebra lies at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, local anesthetic is injected in 3-5 ml aliquots. A volume of 20-25 ml of 0.25% bupivacaine will be used for analgesia on each side depending upon the surgery and requirements. The number of attempts will be noted.Time taken to perform block in minutes will be noted from placing transducer to taking out needle after injecting drug in plane.
Study NCT06728514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral Nerve Block
Description: In PVB technique the patient will be placed in the lateral position, and the superior aspect of the T9,T10 and T11 spinous processes will be identified. Under complete aseptic precautions and after skin infiltration with LA, 23G spinal needle will be inserted perpendicular to the skin, with the goal of contacting the tranverse process. Once the TP is contacted, generally at a depth of 2 to 5 cm in adults, the needle is withdrawn into the subcutaneous tissue, redirected in a caudal direction, and then slowly advanced with the purpose of entering the PVS at an approximate depth of 1.0 to 1.5 cm past the initial contact with the TP. After perforating the costotransverse ligament and negative aspiration for blood, air, or spinal fluid,10 mL of 0.25% bupivacaine will be injected at each level superficial to to the pleural line. Displacement of the pleura line anteriorly will be confirmed proper injection of the local anaesthetic solution. The number of attempts will be noted.
Study NCT06728514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj Bupivacaine
Description: Inj Bupivacaine 0.25% (10ml) in both groups
Study NCT06729216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antifungal susceptibility testing (AFST)
Description: testing the fungal susceptibility to different drugs
Study NCT05267340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARA
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
Study NCT05267340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Education
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
Study NCT05438940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Data Collection
Description: Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
Study NCT05438940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
Study NCT05438940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants will take a survey at baseline and weeks 4,8,12 \& 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
Study NCT06444815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VET3-TGI
Description: Oncolytic vaccinia virus engineered with immunomodulatory transgenes
Study NCT06444815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-pd1 antibody
Study NCT05917470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONCT-534
Description: ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Study NCT04928781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Smoking cessation counseling will be provided following standards set by the institution patients are receiving care at (Dartmouth-Hitchcock Medical Center).
Study NCT06244368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVM±R regimen
Description: Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician.
Study NCT06378424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
Study NCT06378424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Application
Description: Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
Study NCT06378424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration Application
Description: With individuals in this group, the Buzzy® device was used to provide vibration. The Buzzy® device, at room temperature, was placed by the researcher on the peripheral intravenous catheterization application area before the application was performed. For one minute before the application, a slight, non-discomforting vibration was applied to the intervention area. As the Buzzy® device can be used more than once, it was disinfected after each use and before being used with another individual. In this study, the body of the device was used, and only vibration was applied to the individuals in this group.
Study NCT05374447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy
Description: Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
Study NCT05374447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy
Description: Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
Study NCT04214210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Family Gene Toolkit
Description: Five web-based modules designed to increase knowledge of cancer genetics (Module 1); provide decisional support for genetic testing (Module 2); increase active coping to common challenges faced by HBOC families (Module 3); provide a five-steps, skills-building communication training (Module 4); increase knowledge about management of hereditary cancer risk based on the most updated recommendations from the National Comprehensive Cancer Network (Module 5).
Study NCT04214210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted intervention
Description: The comparison website will provide targeted information about HBOC and enable sharing genetic test results.The Korean team will define the contents of the comparison website that will mimic the structure and function of a website already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and three Swiss national languages. The tailored and the targeted platform will be technically implemented in the same system, to track access and usage of the platform and provide a user-friendly experience.
Study NCT05031442 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RH1 (low waist)
Description: Investigational product variant 1 low waist
Study NCT05031442 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reference variant 1 (low waist)
Description: Reference product variant 1
Study NCT05031442 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RC2 (high waist)
Description: Investigational product variant 2 high waist
Study NCT05031442 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reference variant 2 (high waist)
Description: Reference product variant 2
Study NCT05750758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 2.5mg bid for 1m
Study NCT05178472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive SOC immunotherapy